Skip to content
value.today

Kronos Bio, Inc.

🇺🇸 New York, New York, USABiotechnologyFounded 2017

Formerly Ponderosa Biosciences, Inc.

Total raised
$123 M
2 rounds on record
Latest round
$105 M
Jul 2019
First round on record
May 2018
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Kronos Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2019$105 MNo. 2$50 to $250 million

Kronos Bio, Inc.: Raise no. 2, Jul 2019

Investors in this round

50 investors had bought by the notice of Jul 15, 2019: 50 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Kronos Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$105 M of $105 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$360,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David M. Tanen · Executive Officer, Director, Promoter
  • Norbert Bischofberger, Ph.D. · Executive Officer, Director
  • Philip C. Gutry · Executive Officer
  • Sean A. Algeo · Executive Officer
  • Arie S. Belldegrun, M.D. · Director
  • Jacob C. Loven · Director
  • John C. Martin, Ph.D. · Director
  • Joshua A. Kazam · Director
  • Otello C. Stampacchia, Ph.D. · Director
  • Rebecka C. Belldegrun, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David M. Tanen, Secretary. Source: SEC Form D, newest notice filed Jul 15, 2019. Read the notice at the SEC.

equitySEC
May 2018$18 MNo. 1$10 to $50 million

Kronos Bio, Inc.: Raise no. 1, May 2018

Investors in this round

32 investors had bought by the notice of Jun 5, 2018: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Kronos Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$360,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher A. Wilfong · Executive Officer
  • David M. Tanen · Executive Officer, Director, Promoter
  • Norbert Bischofberger, Ph.D. · Executive Officer, Director
  • Arie S. Belldegrun, M.D. · Director
  • John C. Martin, Ph.D. · Director
  • Joshua A. Kazam · Director
  • Otello C. Stampacchia, Ph.D. · Director
  • Rebecka C. Belldegrun, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David M. Tanen, Secretary. Source: SEC Form D, newest notice filed Jun 5, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Kronos Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2019).

    SEC Form D · Jul 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2019

That is all the official record says: Kronos Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Kronos Bio, Inc.
InvestorKindAmountRoundRoleSource
Bischofberger Norbert W. & Inger A. Revocable Inter Vivos TrustOthernot statednot statedHeld Series Seed and A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
David M. TanenPersonnot statednot statedHeld Series Seed preferred stock, director (Form 3, 2020)SEC Form 3
John C. MartinPersonnot statednot statedHeld Series Seed preferred stock, director (Form 3, 2020)SEC Form 3
Joshua A. KazamPersonnot statednot statedHeld Series Seed and A preferred stock, director (Form 3, 2020)SEC Form 3
Omega Fund V GP, L.P.Fund or asset managernot statednot statedHeld Series Seed and A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Omega Fund V GP Manager, Ltd.Fund or asset managernot statednot statedHeld Series Seed and A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Omega Fund V, L.P.Fund or asset managernot statednot statedHeld Series Seed and A preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 50 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kronos Bio, Inc.
NameRoleNamed in
David M. TanenExecutive officerJul 2019
Norbert Bischofberger, Ph.D.Executive officerJul 2019
Philip C. GutryExecutive officerJul 2019
Sean A. AlgeoExecutive officerJul 2019
Christopher A. WilfongExecutive officerJun 2018
Arie S. Belldegrun, M.D.DirectorJul 2019
David M. TanenDirectorJul 2019
Jacob C. LovenDirectorJul 2019
John C. Martin, Ph.D.DirectorJul 2019
Joshua A. KazamDirectorJul 2019
Norbert Bischofberger, Ph.D.DirectorJul 2019
Otello C. Stampacchia, Ph.D.DirectorJul 2019
Rebecka C. Belldegrun, M.D.DirectorJul 2019
David M. TanenPromoterJul 2019